natgillin/translations-raw huggingface dataset:
Det leveres som injektionsvæske, opløsning, til injektion under huden (0,3 mg, 0,6 mg og 0,9 mg) eller som pulver og solvens til klargøring af en suspension til injektion i en muskel (20 mg, 40 mg og 60 mg).
It is available as a solution for injection under the skin (0.3 mg, 0.6 mg and 0.9 mg) or as a powder and solvent to make up a suspension for injection into the muscle (20 mg, 40 mg and 60 mg).
Det leveres som kapsler (200 mg og 250 mg).
It is available as capsules (200 mg and 250 mg).
Det leveres som kapsler (50, 100, 200 mg), som tabletter (50, 200 og 600 mg) og som en oral opløsning (30 mg/ml).
It is available as capsules (50, 100, 200 mg), as tablets (50, 200 and 600 mg), and as an oral solution (30 mg/ml).
Det leveres som lyserøde, kapselformede tabletter (700 mg) og som oral suspension (50 mg/ml).
It is available as pink, capsule- shaped tablets (700 mg) and as an oral suspension (50 mg/ml).
Det leveres som opløselige tabletter. ”Opløselig” betyder, at tabletterne kan opløses (blandes) i vand.
It is available as dispersible tablets. ‘Dispersible’ means that the tablets can be dispersed (mixed) in water.
Det leveres som pulver og solvens, der blandes til injektionsvæske (1,3 eller 5 mg/ml), eller som færdigblandet opløsning i en cylinderampul (3,3 eller 6,7 mg/ml).
It is available as a powder and solvent, which are made up into a solution for injection (1.3 or 5 mg/ml), or as a ready-to-use solution in a cartridge (3.3 or 6.7 mg/ml).
Det leveres som spot-on opløsning i pipetter, der er påfyldt den rette mængde indoxacarb og permethrin til hunde af forskellig vægt (75 mg/240 mg, 150 mg/480 mg, 300 mg/960 mg,
It is available as a ‘spot-on’ solution in pipettes filled with the appropriate amounts of indoxacarb and permethrin for dogs of different weights (75 mg/240 mg, 150 mg/480 mg,
Det leveres som spot-on, opløsning, i applikatorer i fem forskellige styrker til hunde med forskellig kropsvægt.
It is available as a spot-on solution in applicators of five different strengths for use on dogs of different weights.
Det leveres som spot-on, opløsning, i applikatorer i to forskellige styrker til katte med forskellig kropsvægt.
It is available as a spot-on solution in applicators of two different strengths for use in cats of various bodyweights.
Det leveres som spot-on, opløsning, i en applikator til katte.
It is available as a spot-on solution in an applicator for use on cats.
Det leveres som tabletter (100 mg og 400 mg).
It is available as tablets (100 mg and 400 mg).
Det leveres som tabletter (100 mg, 200 mg eller 400 mg) og som oral opløsning (40 mg/ml).
It is available as tablets (100 mg, 200 mg or 400 mg) and as an oral suspension (40 mg/ml).
Det leveres som tabletter (12,5, 25, 50 og 75 mg).
It is available as tablets (12.5, 25, 50 and 75 mg).
Det leveres som tabletter (150 og 500 mg).
It is available as tablets (150 and 500 mg).
Det leveres som tabletter (250 mg).
It is available as tablets (250 mg).
Det leveres som tyggetabletter i fire forskellige styrker til hunde med forskellig vægt.
It is available as chewable tablets in four different strengths for use in dogs of different weights.
Det lille firkantede
The small rectangular window
Det lod ikke til, at brugen af hormonelle præventionsmidler påvirkede det typespecifikke immunrespons over for Gardasil 9.
Use of hormonal contraceptives did not appear to affect the type specific immune responses to Gardasil 9.
Det lukbare adapter skal kasseres, når flasken er tom, og flasken skal kasseres 3 dage efter, den er åbnet, selv hvis den ikke er tom.
The reclosable bottle cap should be discarded when the bottle is empty or after 3 days following opening even if the bottle is not empty.
Det lykkedes desuden at lukke alle fistler hos 55 % af infliximab- behandlede patientersammenlignet med 13 % af patienter behandlet med placebo (p = 0,001).
Additionally, closure of all fistulae was achieved in 55% of infliximab-treated patients compared with 13% of placebo-treated patients (p=0.001).
Det lykkedes desuden at lukke alle fistler hos 55 % af infliximab-behandlede patienter, sammenlignet med 13 % af patienter behandlet med placebo (p = 0,001).
Additionally, closure of all fistulae was achieved in 55% of infliximab-treated patients compared with 13% of placebo- treated patients (p=0.001).
Det lyofiliserede pulver til injektionsvæske i hætteglasset skal rekonstitueres med den leverede solvens (vand til injektionsvæsker) fra den forfyldte injektionssprøjte med den sterile hætteglasadapter til rekonstitution.
The vial of lyophilised product powder for injection must be reconstituted with the supplied solvent (water for injections) from the pre-filled syringe using the sterile vial adapter for reconstitution.
Det maksimale indhold af IgA er 100 mikrogram/ml.
The maximum IgA content is 100 micrograms/ml.
Det maksimale indhold af IgA er 50 mikrogram/ml.
The maximum IgA content is 50 micrograms/ml.
Det maksimale volumen pr. injektion må ikke overskride 1 ml.
The maximum volume per injection should not exceed 1 ml.
Det markerer, at indsprøjtningen næsten er afsluttet.
This indicates the injection is almost
Det medfører hævelse af nethinden og sløret eller forvrænget syn.
When the vitreous humour shrinks with aging, this strong attachment results in a pulling force on the retina, which causes retinal swelling and leads to blurred or distorted vision.
Det medfører, at leveren bliver betændt og opsvulmet.
It causes the liver to become inflamed and swollen .
Det medfører, at leveren bliver opsvulmet (betændt).
It causes the liver to become inflamed and swollen.
Det medførte en forringelse af lægemidlets virkning.
This led to a decrease in the effectiveness of the medicine.
Det mediane antal eksponeringsdage indtil inhibitorudvikling hos disse 32 patienter var 12 (interval 3-49).
The median number of exposure days up to inhibitor development in these 32 patients was 12 (range 3-49).
Det mediane antal tidligere behandlinger var 3,0.
The median number of prior therapies was 3.0.
Det mediane baseline CD4+ celletal var 232 celler/mm3 i begge grupper.
Median baseline CD4+ cell count was 232 cells/mm3 in both groups.
Det medvirker derved til at hindre dannelse af blodpropper.
This means that it helps to prevent blood clots from forming.
Det menes at virke ved at blokere et trin i parasittens metabolisme, der er nødvendigt for dens overlevelse.
It is thought to work by blocking a step in the parasite’s metabolism needed for its survival.
Det menes, at aktivering af AMPA- receptorerne med glutamat er ansvarlig for de fleste hurtige eksitatoriske synaptiske transmissioner i hjernen.
Activation of AMPA receptors by glutamate is thought to be responsible for most fast excitatory synaptic transmission in the brain.
Det menes, at den gavnlige virkning af olanzapin skyldes, at det blokerer receptorerne for de to neurotransmittere 5-hydroxytryptamin (også kaldet serotonin) og dopamin.
It is thought that olanzapine’s beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytryptamine (also called serotonin) and dopamine.
Det menes, at den gavnlige virkning af olanzapin skyldes, at det blokerer receptorerne for neurotransmitternes 5-hydroxytryptamin (også kaldet serotonin) og dopamin.
It is thought that olanzapine’s beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytryptamine (also called serotonin) and dopamine.
Det menes, at det sammen med GM-CSF vil fremme en systemisk antitumor-immunrespons og en effektor-T-cellerespons.
It is thought that together with GM-CSF, it will promote a systemic anti- tumour immune response and an effector T-cell response.
Det menes, at disse symptomer skyldes en forbedring af kroppens immunforsvar, der gør det muligt for kroppen at bekæmpe infektioner, der kan have været til stede uden nogen tydelige symptomer.
It is believed that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Det menes, at disse symptomer skyldes en forbedring af kroppens immunreaktion, hvilket gør kroppen i stand til at bekæmpe infektioner, der kan have været til stede uden nogen tydelige symptomer.
It is thought that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Det menes, at disse symptomer skyldes en forbedring i kroppens immunforsvar, så kroppen kan bekæmpe infektioner, der kan have været til stede uden tydelige symptomer.
It is thought that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Det menes, at olanzapins gavnlige effekt skyldes, at det blokerer receptorerne for neurotransmitterne 5-hydroxytrypamin (også kaldet serotonin) og dopamin.
It is thought that olanzapine’s beneficial effect is due to it blocking receptors for the neurotransmitters 5- hydroxytrypamine (also called serotonin) and dopamine.
Det menes, at olanzapins gavnlige effekt skyldes, at det blokerer receptorerne for neurotransmitterne 5-hydroxytrypamin (også kaldet serotonin) og dopamin.
It is thought that olanzapine’s beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytrypamine (also called serotonin) and dopamine.
Det menes, at PD-1/PD-L1- signalvejen er involveret i at opretholde tolerancen over for fostret under graviditeten.
The PD-1/PD-L1 pathway is thought to be involved in maintaining tolerance to the foetus throughout pregnancy.
Det menes, at rotigotins positive effekt på Parkinsons sygdom opnås ved aktivering af D3-, D2- og D1- receptorerne i nucleus caudatus og putamen i hjernen.
Rotigotine is believed to elicit its beneficial effect on Parkinson’s disease by activation of the D3, D2 and D1 receptors of the caudate-putamen in the brain.
Det menes, at rotigotins virkning primært udøves via dopaminreceptorer.
It is thought that rotigotine may exert its activity mainly via dopamine receptors.
Det mest passende valg af radioaktivt lægemiddel skal også overvejes, hvor det skal tages i betragtning, at der udskilles aktivitet i brystmælken.
breast-feeding, and to what is the most appropriate choice of radiopharmaceuticals, bearing in mind the secretion of activity in breast milk.
Det mest sandsynlige symptom på overdosering er hypotension på grund af Neparvis’ blodtrykssænkende virkning.
Hypotension is the most likely symptom of overdose due to the blood pressure lowering effects of Neparvis.
Det modificerede Invirase/ritonavir-regime reducerede gennemsnittet af maksimal ΔQTcFgennemsnit i den første uge af behandlingen sammenlignet med den samme værdi i raske frivillige, der fik Invirase/ritonavir-standarddosisregimet i TQT-studiet på dag 3 (tabel 4), baseret på en sammenligning på tværs af studier i en anden population.
The modified Invirase/ritonavir regimen reduced mean maximum ΔQTcFdense in the first week of treatment compared with the same value in healthy volunteers receiving the standard Invirase/ritonavir dosing regimen in the TQT study on Day 3, (Table 4) based on cross-study comparison in a different population.
Det modificerede toksin i vaccinen fremstilles ved "rekombinant DNA-teknologi": Det produceres af en bakterie, der har fået indsat et gen (DNA), som gør den i stand til at producere det modificerede toksin.
The modified toxin in the vaccine is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria which have received a gene (DNA) that makes them produce the modified toxin.
Det monoklonale antistof bringer monomethylauristatin E frem til de CD30- positive kræftceller, og når det er kommet ind i kræftcellerne, hindrer det cellerne i at dele sig, så de til sidst dør.
The monoclonal antibody delivers monomethyl auristatin E to the CD30-positive cancer cells, and once inside the cancer cells, it stops them from dividing, and the cancer cells eventually die.
Det muliggør løbende overvågning af benefit/risk-forholdet for lægemidlet.
It allows continued monitoring of the benefice/risk balance of the medicinal product.
Det muliggør løbende overvågning af benefit/risk-forholdet for lægemidlet.
This includes any possible side effects not listed in this leaflet.
Det muliggør løbende overvågning af benefit/risk-forholdetfor lægemidlet.
It allows continued monitoring of the benefit/risk balance of the medicinal product.
Det muliggør løbende overvågning af benefit/risk–forholdet for lægemidlet.
It allows continued monitoring of the benefit/risk balance of the medicinal product.
Det multinationale 2NN studie, indeholdt et farmakokinetisk substudie med 1077 patienter, hvoraf de 391 var kvinder.
In the multinational 2NN study, a population pharmacokinetic substudy of 1,077 patients was performed that included 391 females.
Det multinationale 2NN-studie med Viramune 200 mg indeholdt et farmakokinetisk substudie med 1077 patienter, hvoraf de 391 var kvinder.
In the multinational 2NN study with Viramune immediate-release, a population pharmacokinetic substudy of 1,077 patients was performed that included 391 females.
Det mutagene potentiale er imidlertid blevet vurderet, og alitretinoin tester negativt ved Ames-testen, in vivo-musemikronukleus-assay'en, kromosomaberrationstesten i humane lymfocytter og CHO- cellemutationstesten.
However, the mutagenic potential has been evaluated, and alitretinoin has tested negative in the Ames test, the in vivo mouse micronucleus assay, the chromosomal aberration test in human lymphocytes, and the CHO cell mutation test.
Det må absolut anbefales, at du, hver gang du får Voncento, skriver datoen for behandlingen samt det batchnummer og den mængde, som du har fået, i din behandlingsdagbog.
It is strongly recommended that every time Voncento is given, you should record the date of administration, the batch number and the injected volume in your treatment diary.
Det må besluttes enten at afbryde amningen eller at afbryde/undgå behandlingen.
A decision must be made whether to discontinue breast feeding or to discontinue/abstain from therapy.
Det må desuden ikke anvendes hos patienter med visse andre hjerteproblemer, såsom problemer med elektrisk aktivitet , meget langsom hjerterytme, eller hjerteinsufficiens.
It must also not be used in patients with some other heart problems, such as some problems with the electrical activity, very slow heart beats or heart failure.
Det må desuden ikke anvendes til behandling af svær blødning fra arterier.
It must also not be used to treat severe bleeding from the arteries.
Det må desuden ikke anvendes til patienter, der har fået aplastisk anæmi (nedsat eller ophørt produktion af røde blodlegemer) efter behandling med en hvilken som helst type erytropoietin, patienter med for højt blodtryk, der ikke er velreguleret, patienter, der skal have foretaget et kirurgisk indgreb, og som har svære hjerte-kar-problemer, herunder nyligt hjerteanfald eller slagtilfælde, eller patienter, der ikke må få blodfortyndende medicin.
It must not be used in patients who have developed pure red cell aplasia (reduced or stopped red blood cell production) following treatment with any erythropoietin, patients with hypertension (high blood pressure) that is not controlled, patients about to undergo surgery who have severe cardiovascular (heart and blood vessel) problems including a recent heart attack or stroke, or patients who cannot receive medicines to prevent blood clots.
Det må forventes, at der er behov for en øget dosis ved behandling af yngre børn (under 6 år) med ReFacto AF i forhold til den dosis, der anvendes til voksne og ældre børn.
The need for an increased dose relative to that used for adults and older children should be anticipated when treating younger children (less than 6 years of age) with ReFacto AF.
Det må heller ikke anvendes af patienter, der skal have foretaget større ortopædkirurgiske indgreb, og som har svære hjerte-kar-problemer, herunder nyligt hjerteanfald eller slagtilfælde.
It must also not be used in patients about to undergo major orthopaedic surgery who have severe cardiovascular (heart and blood vessel) problems including a recent heart attack or stroke.
Det må heller ikke anvendes hos gravide eller ammende kvinder eller hos patienter der sideløbende er i af behandling med et andet blodfortyndende lægemiddel.
It must also not be used in pregnant or breastfeeding women or in patients also being treated with another anticoagulant.
Det må heller ikke anvendes hos kvinder, der er gravide i mere end tredje måned, eller hos patienter, der tager medicin indeholdende ciclosporin, itraconazol eller andre lægemidler af typen “potente P-glykoproteinhæmmere” (såsom kinidin).
It must also not be used in women who are more than three months pregnant or in patients taking medicines containing ciclosporin, itraconazole or other medicines known as ‘potent P- glycoprotein inhibitors’ (such as quinidine).
Det må heller ikke anvendes hos patienter med kendt eller formodet mave- eller tarmblokade.
It must also not be used in patients with a known or suspected blockage in their stomach or gut.
Det må heller ikke anvendes hos patienter med livstruende allergi over for æg eller over for nogen af indholdsstofferne i Kanuma.
It must also not be used in patients with life-threatening allergy to eggs or any of Kanuma’s ingredients.
Det må heller ikke anvendes hos patienter, hvis tarme er blokerede, eller som lider af en sygdom, der kræver øjeblikkelig tarmoperation.
Relistor must not be used in patients whose bowel is blocked or who have a condition that needs immediate bowel surgery.
Det må heller ikke anvendes hos patienter, som på noget tidspunkt har haft synstab forårsaget af et problem kaldet non-arteritis anterior iskæmisk opticusneuropati (NAION), der påvirker blodtilførslen til nerven i øjet.
It must not be used in patients who have ever had loss of vision because of a problem called non- arteritic anterior ischaemic optic neuropathy (NAION) that affects the blood flow to the nerve in the eye.
Det må heller ikke anvendes i visse tilfælde, hvor den bagerste del af membranen, der omgiver linsen (linsekapslen), er bristet.
It must also not be used in certain cases where the back part of the membrane that surrounds the lens (the lens capsule) has been ruptured.
Det må heller ikke anvendes sammen med PDE 5- hæmmere (en klasse lægemidler, der anvendes mod pulmonal arteriel hypertension og rejsningsproblemer) eller med nitrater eller nitrogenoxiddonorer (som ofte anvendes til behandling af højt blodtryk, brystsmerter og hjertesygdom eller som narkotika).
It must also not be used together with medicines called ‘PDE 5 inhibitors’ (a class of medicines used for PAH or erectile dysfunction) or with nitrates or nitric oxide donors (often used to treat high blood pressure, chest pain and heart disease, or as recreational drugs).
Det må heller ikke anvendes til drægtige køer eller til kvier, der skal producere mælk til menneskeligt konsum, senere end 2 måneder inden kælvning.
It should also not be used in pregnant cows or heifers which are intended to produce milk for human consumption within 2 months of calving.
Det må heller ikke anvendes til følgende grupper: patienter, der modtager et andet fluoropyrimidin-middel (en gruppe lægemidler mod cancer, der omfatter Teysuno), eller som har haft alvorlige, uventede reaktioner over for fluoropyrimidiner patienter med mangel på enzymet dihydropyrimidin dehydrogenase (DPD) og patienter, der inden for de seneste fire uger er blevet behandlet med et lægemiddel, som hæmmer dette enzym
It must also not be used in the following groups: patients currently receiving another fluoropyrimidine (a group of anticancer medicines that includes Teysuno) or who have had severe and unexpected reactions to fluoropyrimidines; patients with a deficiency of the enzyme dihydropyrimidine dehydrogenase (DPD) as well as patients who, within the previous four weeks, have been treated with a medicine that inhibits this enzyme;
Det må heller ikke anvendes til katte på under to kilo.
It must not be used in cats weighing less than 2 kg.
Det må heller ikke anvendes til kvinder i den fødedygtige alder, medmindre de træffer alle de nødvendige foranstaltninger for at sikre, at de ikke er gravide ved behandlingens begyndelse og ikke bliver det under og i den første tid efter behandlingen.
It must also not be used in women who could become pregnant, unless they take all of the necessary steps to ensure that they are not pregnant before treatment and that they do not become pregnant during or soon after treatment.
Det må heller ikke anvendes til patienter med fremskredent hjerteblok (forstyrrelser i hjerterytmen), patienter med ukontrolleret hypotension og patienter med tilstande såsom slagtilfælde, der påvirker blodforsyningen til hjernen.
It must also not be used in patients with advanced heart block (a type of heart rhythm disorder), patients with uncontrolled hypotension and in patients with conditions such as stroke that affect the blood supply to the brain.
Det må heller ikke anvendes til patienter, der er stærkt overfølsomme over for andre typer antibiotika som penicilliner eller cefalosporiner.
Its use must also be avoided in patients who are severely allergic to other types of antibiotics, such as penicillins or cephalosporins.
Det må heller ikke anvendes til patienter, der har type 1-diabetes (insulinkrævende), og som ikke har ‘C-peptid’ i blodet (en markør for type 1-diabetes).
It should also not be used in patients with type 1 (insulin-dependent) diabetes who do not have any ‘C-peptide’ in their blood (a marker of type 1 diabetes).
Det må heller ikke anvendes til patienter, hvor der er mistanke om, at der tidligere er forekommet en svær allergisk reaktion kaldet ‘allergisk kontaktdermatit’ over for Exelon-depotplaster.
It must also not be used in patients who are suspected to have had in the past an allergic reaction called ‘allergic contact dermatitis’ to Exelon patch.
Det må heller ikke anvendes til patienter, som har diabetisk ketoacidose (høje koncentrationer af ketoner og syrer i blodet), diabetisk prækoma, nyre- eller leverproblemer, sygdomme, som kan påvirke nyrerne, eller en sygdom, som forårsager reduceret iltforsyning til vævene såsom hjerte- eller lungeinsufficiens eller et nyligt hjerteanfald.
It should also not be used in patients who have diabetic ketoacidosis (high levels of ketones and acids in the blood), diabetic pre-coma, problems with their kidneys or liver, conditions that may affect the kidneys, or a disease that causes a reduced supply of oxygen to the tissues such as failure of the heart or lungs or a recent heart attack.
Det må heller ikke anvendes til patienter, som har fået strålebehandling i ansigtet, eller som har tilbagevendende episoder af epistaxis (næseblødning).
It must also not be used in patients who have had facial radiotherapy (treatment with radiation) or who have recurrent episodes of epistaxis (nosebleeds).
Det må heller ikke anvendes til patienter, som tager et af følgende lægemidler, der kan give skadelige bivirkninger, hvis de tages sammen med Invirase: lægemidler, som kan give QT-forlængelse eller PR-forlængelse (en anden form for ændring af hjertefunktionen)
It must also not be used in patients who are taking any of the following medicines, which could cause harmful side effects if taken with Invirase: medicines that could cause QT prolongation or PR prolongation (another type of heart activity alteration);
Det må heller ikke anvendes til patienter, som tager lægemidler, der forsinker nedbrydningen af Thymanax i kroppen, såsom fluvoxamin (et andet antidepressivt lægemiddel) og ciprofloxacin (et antibiotikum).
It must also not be used in patients who are taking medicines that slow down the breakdown of Thymanax in the body, such as fluvoxamine (another antidepressant) and ciprofloxacin (an antibiotic).
Det må heller ikke anvendes til patienter, som tager lægemidler, der forsinker nedbrydningen af Valdoxan i kroppen, såsom fluvoxamin (et andet antidepressivt lægemiddel) og ciprofloxacin (et antibiotikum).
It must also not be used in patients who are taking medicines that slow down the breakdown of Valdoxan in the body, such as fluvoxamine (another antidepressant) and ciprofloxacin (an antibiotic).